The pharmaceutical company GlaxoSmithKline has signed an exclusive worldwide collaboration agreement with Meda's partner Valeant Pharmaceuticals for the Retigabine substance. Meda is entitled to receive significant royalties and certain milestone payments.
Retigabine comprises a new way of affecting potassium channels in the central nervous system. It has been documented to treat epilepsy. According to Valeant, the registration application is expected to be submitted early 2009 in both the U S and in Europe. Broadened indications within the pain area are being pursued, such as neuropathic pain.
"If the sales expectations are realised, this will result in significant annual revenues and profits for a long time which is very positive for Meda's shareholders", said Anders Lönner, CEO Meda.
The sales potential for the first indication (epilepsy) is estimated to be 10 billion SEK on a yearly and worldwide basis. Meda is entitled to receive royalties of 7 per cent on market sales in the US, which account for about 60 per cent of the total world market. In addition, the product will be co-commercialised with GlaxoSmithKline and Valeant in the U S In Europe, the royalty rate can vary from 6 per cent to 8 per cent depending on sales and profitability. In other world markets, the royalty rate is 3 per cent. Meda is also entitled to receive up to a quarter of a billion SEK at certain milestone events that are not linked to sales levels.
Meda AB is an international specialty pharma company that concentrates on marketing and market-adapted product development.